Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Modelling norovirus transmission and vaccination.

Gaythorpe KAM, Trotter CL, Conlan AJK.

Vaccine. 2018 Sep 5;36(37):5565-5571. doi: 10.1016/j.vaccine.2018.07.053. Epub 2018 Jul 31.

2.

The views of the general public on prioritising vaccination programmes against childhood diseases: A qualitative study.

Lasseter G, Al-Janabi H, Trotter CL, Carroll FE, Christensen H.

PLoS One. 2018 Jun 13;13(6):e0197374. doi: 10.1371/journal.pone.0197374. eCollection 2018.

3.

Reactive vaccination as a control strategy for pneumococcal meningitis outbreaks in the African meningitis belt: Analysis of outbreak data from Ghana.

Cooper LV, Stuart JM, Okot C, Asiedu-Bekoe F, Afreh OK, Fernandez K, Ronveaux O, Trotter CL.

Vaccine. 2018 Jan 20. pii: S0264-410X(17)31832-7. doi: 10.1016/j.vaccine.2017.12.069. [Epub ahead of print]

PMID:
29371015
4.

Norovirus transmission dynamics: a modelling review.

Gaythorpe KAM, Trotter CL, Lopman B, Steele M, Conlan AJK.

Epidemiol Infect. 2018 Jan;146(2):147-158. doi: 10.1017/S0950268817002692. Epub 2017 Dec 22.

5.

Investigation of correlates of protection against pharyngeal carriage of Neisseria meningitidis genogroups W and Y in the African meningitis belt.

Cooper LV, Boukary RM, Aseffa A, Mihret W, Collard JM, Daugla D, Hodgson A, Sokhna C, Omotara B, Sow S, Quaye SL, Diallo K, Manigart O, Maiden MCJ, Findlow H, Borrow R, Stuart JM, Greenwood BM, Trotter CL.

PLoS One. 2017 Aug 10;12(8):e0182575. doi: 10.1371/journal.pone.0182575. eCollection 2017.

6.

Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.

Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Préziosi MP, Stuart JM.

Lancet Infect Dis. 2017 Aug;17(8):867-872. doi: 10.1016/S1473-3099(17)30301-8. Epub 2017 May 22.

PMID:
28545721
7.

Hierarchical genomic analysis of carried and invasive serogroup A Neisseria meningitidis during the 2011 epidemic in Chad.

Diallo K, Gamougam K, Daugla DM, Harrison OB, Bray JE, Caugant DA, Lucidarme J, Trotter CL, Hassan-King M, Stuart JM, Manigart O, Greenwood BM, Maiden MCJ.

BMC Genomics. 2017 May 22;18(1):398. doi: 10.1186/s12864-017-3789-0.

8.

Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England.

Christensen H, Trotter CL.

Vaccine. 2017 Jan 5;35(2):208-211. doi: 10.1016/j.vaccine.2016.11.076. Epub 2016 Dec 5.

9.

Barriers and facilitators to uptake of the school-based HPV vaccination programme in an ethnically diverse group of young women.

Batista Ferrer H, Trotter CL, Hickman M, Audrey S.

J Public Health (Oxf). 2016 Sep;38(3):569-577. Epub 2015 Jun 7.

10.

Alternative Molecular Methods for Improved Detection of Meningococcal Carriage and Measurement of Bacterial Density.

Manigart O, Okeakpu J, Odutola A, Jarju S, Foster-Nyarko E, Diallo K, Roca A, Kampmann B, D'Alessandro U, Sow S, Antonio M, Maiden MJ, Borrow R, Stuart JM, Trotter CL, Greenwood BM.

J Clin Microbiol. 2016 Nov;54(11):2743-2748. Epub 2016 Aug 31.

11.

Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.

Christensen H, Irving T, Koch J, Trotter CL, Ultsch B, Weidemann F, Wichmann O, Hellenbrand W.

Vaccine. 2016 Jun 17;34(29):3412-9. doi: 10.1016/j.vaccine.2016.04.004. Epub 2016 Apr 22.

12.

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.

Karachaliou A, Conlan AJ, Preziosi MP, Trotter CL.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S594-600. doi: 10.1093/cid/civ508.

13.

Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali.

Basta NE, Borrow R, Berthe A, Onwuchekwa U, Dembélé AT, Almond R, Frankland S, Patel S, Wood D, Nascimento M, Manigart O, Trotter CL, Greenwood B, Sow SO.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S578-85. doi: 10.1093/cid/civ513.

14.

Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.

Tall H, Yaro S, Kpoda HB, Ouangraoua S, Trotter CL, Njanpop Lafourcade BM, Findlow H, Bai X, Martin C, Nwakamma I, Ouedraogo JB, Gessner BD, Borrow R, Mueller JE.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S540-6. doi: 10.1093/cid/civ519.

15.

Response thresholds for epidemic meningitis in sub-Saharan Africa following the introduction of MenAfriVac®.

Trotter CL, Cibrelus L, Fernandez K, Lingani C, Ronveaux O, Stuart JM.

Vaccine. 2015 Nov 17;33(46):6212-7. doi: 10.1016/j.vaccine.2015.09.107. Epub 2015 Oct 14.

PMID:
26463444
16.

Competition, coinfection and strain replacement in models of Bordetella pertussis.

Nicoli EJ, Ayabina D, Trotter CL, Turner KM, Colijn C.

Theor Popul Biol. 2015 Aug;103:84-92. doi: 10.1016/j.tpb.2015.05.003. Epub 2015 May 30.

17.

Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.

Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, Slack M, George R, Lim WS.

Eur Respir J. 2015 Jun;45(6):1632-41. doi: 10.1183/09031936.00183614. Epub 2015 Mar 18.

18.

Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013.

Gamougam K, Daugla DM, Toralta J, Ngadoua C, Fermon F, Page AL, Djingarey MH, Caugant DA, Manigart O, Trotter CL, Stuart JM, Greenwood BM.

Emerg Infect Dis. 2015 Jan;21(1):115-8. doi: 10.3201/eid2101.140256.

19.

Authors' reply to Rappuoli and colleagues, Black, and Glennie and colleagues.

Christensen H, Trotter CL, Hickman M, Edmunds WJ.

BMJ. 2014 Nov 13;349:g6758. doi: 10.1136/bmj.g6758. No abstract available.

PMID:
25394639
20.

Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.

Christensen H, Trotter CL, Hickman M, Edmunds WJ.

BMJ. 2014 Oct 9;349:g5725. doi: 10.1136/bmj.g5725.

Supplemental Content

Loading ...
Support Center